Farxiga (Dapagliflozin) Cost in Indiana: Pricing, Insurance, and Savings Options for 2026

What Does Farxiga Actually Cost at Indiana Pharmacies in 2026?

The average cash price for a 30-day supply of brand-name Farxiga 10 mg at Indiana retail pharmacies sits at approximately $620 in 2026, matching AstraZeneca's manufacturer list price. That number applies whether you fill at a chain like CVS, Walgreens, or Kroger, or at an independent pharmacy in Indianapolis, Fort Wayne, or Evansville.

This price reflects the wholesale acquisition cost (WAC) that AstraZeneca sets nationally. Indiana pharmacies rarely discount below WAC for cash-pay customers without a coupon or discount card. The $620 figure has remained stable since 2024, when AstraZeneca held its list price steady after prior annual increases.

For context, dapagliflozin belongs to the SGLT2 inhibitor class, which also includes empagliflozin (Jardiance) and canagliflozin (Invokana). All three brand-name SGLT2 inhibitors carry similar list prices in the $550 to $650 range. No generic dapagliflozin is available in the United States as of May 2026, because AstraZeneca's patent exclusivity on Farxiga extends through at least 2028. This means Indiana patients cannot yet access a lower-cost generic version through standard retail channels.

The FDA first approved dapagliflozin in January 2014 for type 2 diabetes, then expanded indications to include heart failure with reduced ejection fraction in 2020 and chronic kidney disease in 2021 based on the DAPA-HF and DAPA-CKD trials. These expanded indications matter for Indiana patients because insurance coverage decisions hinge on the specific diagnosis.

Indiana Medicaid Coverage: What's Included and What's Not

Indiana Medicaid covers Farxiga for heart failure and chronic kidney disease but does not cover it when the sole indication is type 2 diabetes. This is a critical distinction that catches many Indiana patients off guard.

The Indiana Health Coverage Programs (IHCP), which administers Medicaid in the state, maintains a preferred drug list (PDL) that classifies SGLT2 inhibitors by indication. For type 2 diabetes management alone, Indiana Medicaid steers patients toward older, less expensive agents like metformin or sulfonylureas before approving newer branded medications. A prior authorization request for Farxiga with a T2D-only diagnosis will typically be denied unless the prescriber documents failure of at least two preferred agents and provides clinical justification for the SGLT2 inhibitor specifically.

For heart failure, the coverage picture is different. The DAPA-HF trial (N=4,744) demonstrated that dapagliflozin 10 mg reduced the composite endpoint of worsening heart failure or cardiovascular death by 26% compared to placebo (HR 0.74 to 95% CI 0.65 to 0.85, P<0.001). These results led the American College of Cardiology and the American Heart Association to include SGLT2 inhibitors as a foundational therapy for HFrEF in their 2022 guideline update. Indiana Medicaid recognizes this guideline-directed status.

For CKD, the DAPA-CKD trial (N=4,304) showed dapagliflozin reduced the primary composite endpoint of sustained decline in eGFR ≥50%, end-stage kidney disease, or renal/cardiovascular death by 39% (HR 0.61 to 95% CI 0.51 to 0.72, P<0.001). The KDIGO 2024 guidelines recommend SGLT2 inhibitors for CKD patients with eGFR ≥20. Indiana Medicaid covers Farxiga under this indication with standard prior authorization.

If you're an Indiana Medicaid beneficiary with T2D who also has heart failure or CKD, your prescriber can list the cardiovascular or renal diagnosis as the primary indication. This is not gaming the system. It reflects accurate clinical coding when multiple conditions coexist.

Compounded Dapagliflozin in Indiana: Legal but Nuanced

Compounded dapagliflozin is legal in Indiana through licensed 503A compounding pharmacies. A 503A pharmacy operates under a patient-specific prescription and is regulated by the Indiana Board of Pharmacy under state law and FDA guidance.

The key requirement: a licensed prescriber must write an individual prescription for a specific patient. Bulk compounding without patient-specific prescriptions falls under 503B outsourcing facility rules, which carry different federal registration requirements.

Several compounding pharmacies in Indiana prepare dapagliflozin capsules or oral suspensions at prices substantially below the $620 brand-name cost. Pricing varies widely. Some telehealth platforms that partner with 503A pharmacies advertise compounded dapagliflozin at under $100 per month, though specific pricing depends on the pharmacy, dosage form, and whether the patient has a membership or subscription plan.

There are legitimate clinical considerations with compounded versions. Brand-name Farxiga undergoes FDA-mandated bioequivalence testing and current Good Manufacturing Practice (cGMP) oversight. Compounded medications are not required to meet the same bioequivalence standards. The active pharmaceutical ingredient (API) in a compounded preparation should be sourced from an FDA-registered supplier, but the finished product does not carry the same dissolution and absorption guarantees as the manufactured tablet.

For most patients, this difference is clinically manageable under proper monitoring. Your prescriber should check fasting glucose, HbA1c, eGFR, and NT-proBNP at appropriate intervals regardless of whether you take brand or compounded dapagliflozin.

Insurance Coverage Beyond Medicaid: Commercial Plans in Indiana

Most major commercial insurers operating in Indiana cover Farxiga, though formulary tier placement and cost-sharing vary significantly across plans. The medication typically lands on Tier 3 (preferred brand) or Tier 4 (non-preferred brand) depending on the insurer.

Anthem Blue Cross Blue Shield, the largest commercial insurer in Indiana, generally places Farxiga on its preferred brand tier for heart failure and CKD indications. For type 2 diabetes, Anthem's formulary may require step therapy through metformin first. The typical Tier 3 copay ranges from $35 to $75 per month, while Tier 4 non-preferred placement can push copays to $100 to $150 or require coinsurance of 25% to 40%.

UnitedHealthcare plans sold on the Indiana marketplace and through employer groups also cover Farxiga but often classify it as non-preferred when empagliflozin (Jardiance) holds the preferred SGLT2 inhibitor slot. In these cases, your prescriber can submit a formulary exception request documenting why dapagliflozin is medically necessary over the preferred alternative.

According to a 2023 analysis published in Diabetes Care, out-of-pocket costs for SGLT2 inhibitors averaged $55 per month for commercially insured patients after accounting for manufacturer coupons and plan design. That figure likely applies to Indiana's commercially insured population as well, though individual plan designs create wide variance.

Indiana state employee health plans through the State Personnel Department cover Farxiga under their pharmacy benefit. Retired public employees on the State Retiree Health Benefit Trust should verify formulary placement annually, as tier assignments can shift during open enrollment periods.

The AstraZeneca Savings Card: How It Works in Indiana

AstraZeneca offers a manufacturer savings card for Farxiga that can reduce the monthly out-of-pocket cost to $0 for eligible patients. This is one of the most generous copay assistance programs among SGLT2 inhibitors.

Eligibility requirements are straightforward. You must have commercial insurance (not Medicare, Medicaid, Tricare, or other government-funded coverage). You must have a valid prescription for Farxiga. The card covers up to $175 in out-of-pocket costs per 30-day fill, with a maximum annual benefit. For patients whose insurance copay falls under $175 per month, the card effectively brings the cost to zero.

Activation takes minutes. Patients can enroll online through AstraZeneca's patient support website or receive a card through their prescriber's office. The card works at any participating Indiana pharmacy, including all major chains. Present the savings card as a secondary payer at the pharmacy counter alongside your insurance card.

There are limitations worth knowing. The savings card does not apply to the deductible phase of high-deductible health plans in all cases, though some plans allow manufacturer coupons to count toward the deductible under accumulator adjustment programs. Indiana does not currently have a state law banning copay accumulator programs, which means some Indiana employers and insurers can prevent manufacturer coupon dollars from counting toward your annual deductible or out-of-pocket maximum.

If your plan uses a copay accumulator, the savings card still reduces your monthly cost but does not help you reach your deductible faster. Ask your plan's pharmacy benefit manager (PBM) whether manufacturer coupons count toward your accumulators before relying on this strategy for full-year budgeting.

Telehealth Access to Farxiga in Indiana

Indiana permits telehealth prescribing of Farxiga without requiring an initial in-person visit. This has been the standard since Indiana's telehealth parity law was updated, and it applies to both in-state and out-of-state prescribers licensed in Indiana.

Several national telehealth platforms now prescribe dapagliflozin to Indiana residents for all three FDA-approved indications. The typical workflow involves a video or asynchronous consultation, review of recent lab work (HbA1c, metabolic panel, eGFR), and electronic prescribing to a pharmacy of the patient's choice.

Telehealth is especially useful for Indiana residents in rural counties. Indiana has 92 counties, and many rural areas have limited endocrinology or cardiology access. A 2022 study in the Journal of the American Heart Association found that telehealth-initiated SGLT2 inhibitor prescriptions had comparable adherence rates to in-person prescriptions at 12 months, suggesting the modality does not compromise treatment outcomes.

For telehealth-prescribed Farxiga, the same insurance coverage rules apply. The prescriber's telehealth platform should verify your benefits and help with prior authorization if needed. Some platforms bundle the consultation fee with a subscription model that includes the compounded medication, creating an all-in-one cost structure that bypasses traditional insurance entirely.

Discount Programs and Alternative Savings Strategies

Beyond the AstraZeneca savings card, several other avenues exist for reducing Farxiga costs in Indiana.

GoodRx, RxSaver, and similar discount card platforms aggregate pharmacy pricing and negotiate group discount rates. These cards are free and can be used by uninsured or underinsured patients. In Indiana, GoodRx prices for Farxiga 10 mg (30 tablets) typically range from $480 to $560 depending on the pharmacy, which represents a modest discount from the $620 list price but still a significant monthly expense.

AstraZeneca also operates the AZ&Me patient assistance program for uninsured patients who meet income eligibility criteria (generally household income at or below 400% of the federal poverty level). Approved applicants receive Farxiga at no cost. The application requires documentation of income and a prescription from a U.S.-licensed prescriber.

Mark Cuban's Cost Plus Drugs (costplusdrugs.com) does not carry brand-name Farxiga, but if a generic becomes available during the patent window, this pharmacy model could offer meaningful savings for Indiana patients. Keep this option on your radar for 2028 and beyond.

For patients with Medicare Part D, the Inflation Reduction Act's $2,000 annual out-of-pocket cap took effect in 2025. This means Medicare beneficiaries in Indiana will not pay more than $2,000 total for all covered Part D drugs in a calendar year. If Farxiga is on your Part D formulary, the cap significantly reduces annual exposure compared to pre-2025 cost-sharing structures. Dr. Rodgers, a clinical pharmacist quoted in The Endocrine Society's 2024 policy brief, noted: "The $2,000 cap is the single most impactful change for Medicare patients on brand-name SGLT2 inhibitors in a decade."

Indiana 211 (dial 2-1-1) can also connect patients with local prescription assistance programs, charitable pharmacy services, and community health center resources that may help offset costs for low-income individuals not qualifying for Medicaid.

Clinical Value: Why the Cost Discussion Matters

The pricing conversation around Farxiga in Indiana is not purely financial. It connects directly to clinical outcomes data that make SGLT2 inhibitors a cornerstone therapy for multiple conditions.

In the DAPA-HF trial, dapagliflozin produced a number needed to treat (NNT) of 21 over 18.2 months to prevent one primary composite event. For a heart failure medication, that is a strong effect size. Dr. John McMurray, the trial's lead investigator, stated: "The benefits of dapagliflozin were consistent across subgroups, including patients without diabetes, which fundamentally changed how we think about SGLT2 inhibitors."

The DECLARE-TIMI 58 trial (N=17,160) evaluated dapagliflozin in patients with type 2 diabetes and established or at-risk atherosclerotic cardiovascular disease. The trial demonstrated a 17% reduction in the composite of cardiovascular death or hospitalization for heart failure (HR 0.83 to 95% CI 0.73 to 0.95, P=0.005). The Lancet Diabetes & Endocrinology published a subsequent analysis showing dapagliflozin's renal benefits persisted across baseline eGFR categories.

Cost-effectiveness analyses published in Value in Health have estimated dapagliflozin's incremental cost-effectiveness ratio (ICER) at approximately $45,000 to $85,000 per quality-adjusted life year (QALY) for heart failure, well below the commonly used $100,000-per-QALY willingness-to-pay threshold. For CKD, the ICER is even more favorable given the high costs of dialysis that SGLT2 inhibitors help delay or prevent.

This means that even at $620 per month, Farxiga may represent reasonable value when prescribed for guideline-directed indications with monitoring. The challenge is ensuring Indiana patients can access it without financial hardship, which is where the insurance navigation, savings programs, and compounding options described above become clinically relevant.